The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation

Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with valsartan in an outpatient practice.

Material and Methods. The study included 90 patients with chronic FMR, who were observed for 12 months. They received sacubitril/valsartan or valsartan. Efficiency criteria were: the difference between groups in scores according to the Kansas questionnaire for patients with cardiomyopathy; MR degree parameters (change in effective regurgitation orifice area, vena contracta width, MR volume and MR fraction); indicators of the severity of myocardial remodeling (left ventricular EF; the level of N-terminal brain natriuretic propeptide), exercise tolerance based on a 6-minute walk test, a change in the functional class of heart failure according to NYHA.

Results. In a treatment efficacy analysis, the Kansas City Cardiomyopathy Questionnaire–Overall Summary Score improved by 22.1 points in the sacubitril/valsartan group and by 4.5 points in the valsartan group (p<0.001). EF, exercise tolerance, and the number of patients transitioning from NYHA functional class III to II increased in the sacubitril/valsartan group (p<0.05). Also, in this group, the effective area of the regurgitation opening, the width of the vena contracta, the volume of regurgitation, the fraction of regurgitation, and the level of N-terminal brain natriuretic propeptide (p<0.05) decreased more pronouncedly (p<0.05).

Conclusion. Compared with valsartan, treatment with sacubitril/valsartan leads to a significant improvement in the quality of life in patients with FMR and HF with reduced EF, which is largely associated with a change in NT-proBNP, echocardiographic characteristics of the severity of MR and the degree of myocardial remodeling.

1. Vinogradova NG, Polyakov DS, Fomin IV. Analysis of mortality in patients with CHF after decompensation during long-term follow-up in specialized medical care and in real clinical practice. Kadiologiia. 2020;60(4):91-100 (In Russ.) DOI: 10.18087/cardio.2020.4.n1014.

2. Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13 (In Russ.) DOI: 10.15829/1560-4071-2016-8-7-13.

3. Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCHA-CHF study. Kadiologiia. 2021;61(4):4- 14 (In Russ.) DOI:10.18087/cardio.2021.4.n1628.

4. Mareev VYu, Fomin IV, Ageev FT, et al. Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kadiologiia. 2018;58(6S):8-164 (In Russ.) DOI:10.18087/cardio.2475.

5. Dziadzko V, Clavel MA, Dziadzko M, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet. 2018;391(10124):960-9. DOI:10.1016/S0140-6736(18)30473-2.

6. Imaev TE, Komlev AE, Kuchin IV, et al. Transcatheter methods in the treatment of mitral valve pathology: current state of the problem. Part 1. Cardiology Bulletin. 2020;(1):4-13 (In Russ.) DOI:10.36396/MS.2020.16.1.001.

7. Hurlburt A. CMS proposes patient-centered outcome measure for the SNFs in 2018 [cited 2022 Feb 20]. Available from: https://www.healthleadersmedia.com/clinical-care/cms-proposes-patient-reported-outcome-measure-snfs-2018.

8. FDA Medical Device Development Tool (MDDT) Qualification Decision Summary For Kansas City Cardiomyopathy Questionnaire (KCCQ) [cited 2022 Feb 20]. Available from: https://www.fda.gov/media/108301/download.

9. Khariton Y, Fonarow GC, Arnold SV, et al. Association between sacubitril/valsartan initiation and health status outcomes in heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;7(11):942- 4. DOI:10.1016/j.jchf.2019.05.016.

10. Arutyunov GP, Evzerikhina AV, Rylova AK, et al. Clinical effectiveness of different forms of continuous education of patients suffering from chronic heart failure. Cardio Somatics. 2013;4(1): 55-62 (In Russ.)

11. Kovalenko VN, Voronkov LG. The problem of quality of life in chronic heart failure. Eurasian Heart Journal. 2012;(1):49-56 (In Russ.) DOI: 10.38109/2225-1685-2012-1-49-56.

12. Mc Murray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004]. DOI:10.1056/NEJMoa1409077.

13. Lewis EF, Claggett BL, Mc Murray JJV, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10(8):e003430. DOI:10.1161/CIRCHEARTFAILURE.116.003430.

14. Ryazanov AS, Kapitonov KI, Makarovskaya MV, et al. The results of the use of angiotensin receptor inhibitors and neprilysin in secondary functional mitral regurgitation in outpatient practice. Bulletin of RAMN. 2020;75(5):514-22 (in Russ.) DOI:10.15690/vramn1462.

15. Sergeeva LI. Mitral regurgitation and myocardial remodeling. Heartfailure. 2007;4:191-192 (In Russ.)

16. Januzzi JL, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019;322(11):1085-95. DOI:10.1001/jama.2019.12821.

17. Kang DH, Park SJ, Shin SH, et al. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation. PRIME Study. Circulation. 2019;139:1354-65. DOI:10.1161/CIRCULATIONAHA.118.037077.

18. Januzzi JL, Butler CJ, Fombu E, et al. Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF) Am Heart J. 2018;199:130-6. DOI:10.1016/j.ahj.2017.12.021.

19. Lewis EF, Claggett BL, McMurray JJV, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10(8):e003430. DOI:10.1161/CIRCHEARTFAILURE.116.003430.

20. Desai AS, Solomon SD, Shah AM, et al. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2019;322(11):1077-84. DOI:10.1001/jama.2019.12843

21. Piña IL, Camacho A, Ibrahim NE, et al. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol HF. 2021;(1)42- 51. DOI:10.1016/j.jchf.2020.09.012.

22. Thomas M, Khariton Y, Fonarow, GC, et al. Association of Changes in Heart Failure Treatment With Patients' Health Status: Real-World Evidence From CHAMP. JACC Heart Fail. 2019;7(7):615-25. DOI:10.1016/j.jchf.2019.03.020.